Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, Serina Therapeutics, Inc. reported revenue of $0M, up 132.1% year over year. Operating margin was -18478.5% and net margin -14755.4%, on a free-cash-flow margin of -13856.9% with capital expenditure at 45.4% of revenue. Every figure is computed directly from SER's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $0M | -18478.5% | -14755.4% |
| FY2024 | $0M | -30442.9% | -19894.6% |
| FY2023 | $3M | -99.2% | 167.1% |
| FY2022 | $0M | -20514.7% | -30770.6% |
| FY2021 | $0M | -5509.0% | -6024.3% |
How does SER compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.